Short answer
Phathom Pharmaceuticals, Inc. (PHAT) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results released for quarter ended September 30, 2026.
Phathom Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results released for quarter ended September 30, 2026
- Exhibit 99.1 contains the substantive earnings figures and management commentary
- Disclosure furnished under Regulation FD, not deemed filed under Exchange Act Section 18 liabilities
Item EX-99.1 · Exhibit EX-99.1
- Q3 net revenue $84.7M, up 71% year over year and 14% sequentially, confirming accelerating VOQUEZNA commercialization
- Approximately 380,000 prescriptions filled, including 248,000 covered prescriptions, supporting improving payer access
- Positive operating cash flow for the second consecutive quarter, with cash $184.6M at September 30
- GAAP net loss narrowed to $13.9M from $30.0M, while adjusted net income reached $3.0M
- 2026 guidance reaffirmed: net revenue $310–325M, gross margin approximately 80%, non-GAAP operating expenses $235–245M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Phathom Pharmaceuticals, Inc. 8-K filings
Get the next PHAT 8-K as it lands
Follow PHAT for push alerts, or ask the research agent what this filing means.